Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic lethality strategies to treat relevant cancers. …
Patrys' says preclinical data supports synthetic lethality mechanism
March 15, 2023 Australian Biotech
Latest Video
New Stories
-
Ombudsman's 'State of the Health Funds Report' confirms a decline in complaints
March 20, 2023 - - Other Health -
Aurora Healthcare and Medibank partner to boost access to mental health care
March 20, 2023 - - Other Health -
Bupa puts First Nations Health at the centre of Reconciliation Action Plan
March 20, 2023 - - Latest News -
Monash University in new partnership with leading Israeli research hospital
March 20, 2023 - - Australian Biotech -
Australian company Clinuvel initiates second trial of new anti-stroke candidate
March 20, 2023 - - Australian Biotech -
Organon partners with foundation to relaunch 'No Limits 4 Girls' program
March 20, 2023 - - Latest News -
Moderna officially launches Australian mRNA fellowship program
March 20, 2023 - - Latest News